Orphan designation was granted by the FDA to Curis (CRIS) Inc’s emavusertib for the treatment of primary central nervous system lymphoma, according to a post to the agency’s website.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRIS: